Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Inhibition of the HSP90 chaperone leads to degradation of the HER2 receptor. The HSP90 inhibitor tanespimycin in combination with trastuzumab is active in patients with HER2-overexpressing metastatic breast cancer. This combination is one of several HER2-targeted therapies that will significantly improve the outcome of patients with this subtype of breast cancer.

Original languageEnglish (US)
Pages (from-to)4919-4921
Number of pages3
JournalClinical Cancer Research
Volume17
Issue number15
DOIs
StatePublished - Aug 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?'. Together they form a unique fingerprint.

  • Cite this